This document is written for medical doctors, clinical officers, medical assistants, nurses, midwives, health surveillance assistants (HSAs), and medical records clerks who are working in public and private sector health facilities in Malawi. It is designed to be a practical guide for implementation... of integrated HIV services.
more
This document has been developed as a guide to allinstitutions producing health care waste in planning and implementation of interventions that will reduce mismanagement of hazardous waste in Zambia.The National Health-Care Waste Management Plan for 2015 to 2019 provides an overv...iew of the situation analysis, the proposed activities and the health care facility waste generating processes in Zambia and presents options for minimizing health-care waste generation through source reduction. The hazardous wastes generated by health care facilities are a challenge in Zambia as handling, storage, transportation and final disposal leaves much to be desired.
more
This 277 page pocketbook is a summary of the emergency components of basic neonatal and older infants hospital care from our 900 page textbook “International Maternal & Childhealth Care. A practical manual for hospitals worldwide”.
If you work in a hospital in a low income country - providin...g free care - you are probably intitled to FREE copies of these books. MCAI will send them to you, all you have to do is to read our Flyer and fill in the request form.
more
Can J Anesth/J Can Anesth June 2018, Volume 65, Issue 6, pp 698–708
Endorsed by the CCM Georgia on April 15th 2015
Accessed: 26.09.2019
Single TB and HIV Concept Note Albania 2016-2018 27 April 2015
Case study
Alliance Ukraine’s experience integrating HIV, harm reduction and sexual and reproductive health programming
A National Service Programme for All Children with Special Needs and their Families
In Myanmar, we estimate that at least 40% of children require ECI services for short to longer periods of time. At present, 35.1% of Myanmar children are moderately to severely stunted; all of these children are l...ikely to have one or more developmental delays. In addition, at least 5% to 12% of the nation’s children will be identified to have disabilities, chronic diseases or atypical behaviours.
Over time, approximately 70% of the children who will be served will improve in their development, attain expected levels of development for their age, and will consolidate their gains within one to two years. Other children, approximately 30%, will have lifelong disabilities or other conditions, and ECI services usually greatly improve their development and help them to achieve their full potential.
more
A training tutorial for healthcare professionals
This ECDC tutorial presents the fundamental concepts of personal protective equipment (PPE) and barrier nursing to support preparedness in hospitals across Europe. It provides practical information on the proper use of PPE at the point of care, inclu...ding technical requirements and procurement aspects
more
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva...nt partners in their discussions to identify the best approaches to ensure the accelerated evaluation and use of available or near-term therapies and vaccines for the treatment and prevention of EVD. The document calls for a coordinated effort by the international community to remove unnecessary obstacles towards this goal.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Third Edition: Revised October 2012